Results for “africa” 961 found
It turns out that Homo Sapiens is not all that different from other, early proto-human species, such as Neanderthals. They are the “closest things to us.” Denisovans, etc. We killed them off. (We also are likely to mostly kill off chimpanzees, zoos and research labs excluded.) Therefore the best prediction is that we kill us off too. The other species like us died through mass violence at the hands of humans. We don’t have many data points, but they all seem to end the same way.
You might think a) “we are really good at killing off other species,” rather than b) “we are really good at killing things off.” Therein lies some hope. Signs of cross-national solidarity thus should make you much more optimistic about the future.
How’s that African vaccine distribution program coming?
Alternative dosing is finally getting some attention. This story in Nature recounts some of the recent arguments and evidence:
Two jabs that each contained only one-quarter of the standard dose of the Moderna COVID vaccine gave rise to long-lasting protective antibodies and virus-fighting T cells, according to tests in nearly three dozen people1. The results hint at the possibility of administering fractional doses to stretch limited vaccine supplies and accelerate the global immunization effort.
Since 2016, such a dose-reduction strategy has successfully vaccinated millions of people in Africa and South America against yellow fever2. But no similar approach has been tried in response to COVID-19, despite vaccine shortages in much of the global south.
“There’s a huge status quo bias, and it’s killing people,” says Alex Tabarrok, an economist at George Mason University in Fairfax, Virginia. “Had we done this starting in January, we could have vaccinated tens, perhaps hundreds, of millions more people.”
…Sarah Cobey, an infectious-disease researcher at the University of Chicago in Illinois and a co-author of a 5 July Nature Medicine commentary supporting dose ‘fractionation’, disagrees about the need for time-consuming data collection.
“We shouldn’t wait that long,” she says. “People are dying, and we have historical precedent for making very well-reasoned guesses that we think are going to save lives.”
…According to a modelling study published by Tabarrok and other economists, such an approach would reduce infections and COVID-linked deaths more than current policies.
Addendum: The reason for doing the modeling study is precisely to take into account variants like Delta. Our modeling suggests that even with efficacy significantly lower than that suggested by Figure 1 in our paper, alternative doses of more effective vaccines would still provide significant reductions in mortality, even when new variants dominate. The benefits derive from vaccinating more quickly.
1. Barnaby Phillips, Loot: Britain and the Benin Bronzes. Among its other virtues, this book is an excellent “in passing” way to learn about British imperialism and also West African economic collapse. One thing I learned from this book is that Nigeria already has one of the very best collection of these bronzes in the world. It does not seem they are being stolen or ruined, but they are not deployed very effectively either. Recommended.
2. Paul Atkinson, A Design History of the Electric Guitar. “Why is it that so many guitars produced today, not only by Gibson and Fender, but by competing companies, still hark back to the classic designs of the 1950s? Why do so many manufacturers produce designs that are very clearly derivative forms of the Les Paul, the Telecaster, the Stratocaster, the Flying V and the Explorer?” There is now a book on this question, and quite a good one.
3. Cass Sunstein, Sludge: What Stops Us from Getting Things Done and What to Do about It. More people should write books about the most important topics. Have you and your institution done a “sludge audit” lately?
4. Andras Schiff, Music Comes Out of Silence: A Memoir. A well-written and in fact gripping treatment of what makes classical music so wonderful, life as a touring concert pianist, and defecting from Hungary and later being disillusioned by a resurgent European populism. Zoltan Kocsis was at first the more brilliant pianist, but Schiff was more persistent and ended up with a more successful career.
Alex Millmow’s The Gypsy Economist: The Life and Times of Colin Clark covers the now-neglected Australian pioneer of development economics and relative historical optimist.
There is also Kathleen Stock, Material Girls: Why Reality Matters for Feminism, controversial.
1. More. Please forgive the source and the pop-ups.
2. Those new service sector jobs: the rising number of dog lawyers in Canada.
4. The longer-term economic consequences of pandemics, over 220 years.
5. Why Africa’s island states are generally freer (The Economist).
My latest Bloomberg column considers one factor (of many), here is an excerpt:
The male-female imbalance in academic life should be treated as a kind of emergency. But the institutions that address it are slow and bureaucratic.
Now enter the philosophy of wokeism. One way to think of the woke is as a bunch of people who scream about various injustices. But sometimes they don’t have a good plan to address a particular imbalance — and along the way they can inflict a good deal of unjustified damage, for instance by canceling people who make the wrong remarks about gender imbalance or other issues.
These and other criticisms of the woke may well be correct. Still, at the end of the day it has to be recognized that an unresponsive society will generate a lot of unproductive (and unresponsive) screamers. So simply dissecting the weaknesses of woke tactics and arguments misses the point. When practical solutions do not seem to exist, many people will resort to screaming.
This leads to the conclusion that wokeness won’t be defeated as an ideology until there is a more convincing and practical vision of how to undo institutional sclerosis. When that vision comes, it may not be so closely allied with wokeness, which is not excessively concerned with effective administration and incentive compatibility.
Sometimes it even seems that woke forces are effective. Recently some major museums have announced that they are sending back their highly valuable West African bronze sculptures to their countries of origin. Many of those sculptures were stolen by British colonial occupiers, and their restoration would reunite those countries with a significant part of their cultural heritage. This justified change would probably not have occurred without pressure from wokeism.
One underlying theme of the column is that the defects of the Woke — such as excess rigidity — are closely allied to the defects of the society they are protesting against.
Ann Bernstein: From your knowledge of India and Indonesia, what are the core causes of their lack of educational
progress? These are places with highly qualified civil servants and, at least in India’s case, a democratic
government. How do you see this problem? How do we get out of this trap?
Lant Pritchett: I’m head of this very large research project called RISE and we’re spending millions of dollars to
find out the answer to that question. One of the countries where education improvements have been dramatic
is Vietnam. At a tiny fraction of the spending in most countries – including South Africa – Vietnam is achieving
OECD levels of learning. When we asked our Vietnam team why the country has produced this amazing success,
they told us: ‘because they wanted it’.
On one level, that seems silly; on another level, it is the key. Unless, as a society, you agree on a set of achievable
objectives and actually act in a way that reveals that you really want those objectives, you cannot achieve
2. “…despite the socially progressive and egalitarian outlook traditionally associated with liberalism, the most liberal Democrats actually expressed the greatest dehumanization of Republicans.” And how about this clincher: “…and demonstrates the need to develop more constructive outlets for social identity maintenance.”
Some quick comments in response to questions and discussion about my paper Could Vaccine Dose Stretching Reduce COVID-19 Deaths? (written with the all-star cast of Witold Więcek, Amrita Ahuja, Michael Kremer, Alexandre Simoes Gomes, Christopher M. Snyder and Brandon Joel Tan.
1) Any method of increasing vaccine supply will require other changes in the supply chain such as more needles. We think alternative dosing can increase supply quickly with the fewest supply chain disruptions.
2) If we had started Moderna with 50 ug dosing no one would be advocating for 100 ug dosing, thereby halving supply. Rather than “full” or “half-doses,” which bias thinking, we should talk about alternative dosing and ug.
3) Judging by neutralizing antibodies, a 50 ug dose of, for example, Moderna looks to be more effective than standard dosing of many other vaccines including AZ and J&J and much better than others such as Sinovac. Thus alternative dosing is a way to *increase* the quality of vaccine for many people.
4) A 50 ug dose vaccine available today is much higher quality than a 100 ug dose vaccine available one year from now.
5) There are substantial risks from following the current approach, as India and now parts of Africa illustrate. Alternative dosing has a very large upside but small downside since we could switch back to standard doses. For example, Great Britain and Canada delayed the second dose to 12 and 16 weeks respectively but have since reduced the dosing interval as more supplies have become available.
6) The greatest risk to immune escape comes from the unvaccinated. Alternative dosing protects not only those who are dosed but by reducing transmission also reduces risks to the unvaccinated.
7) The key question we face now is not whether there are objections and complications to alternative dosing (there are) the key question is what additional information, available quickly could resolve the most uncertainty? In other words, what can we learn soon that would most aid decision makers?
See the paper for details and also my previous post, A Half Dose of Moderna is More Effective Than a Full Dose of AstraZeneca.
Addendum: It should be clear that this isn’t about the United States, it is about getting high-quality vaccine to places that have little to none.
…the magnitude of the earnings disparities along the perceived attractiveness continuum, net of controls, rivals and/or exceeds in magnitude the black-white race gap and, among African-Americans, the black-white race gap and the gender gap in earnings.
1. It is often the educated (and often left-wing) coastal elite that commits the most lookism and also enforces it through internal norms of dress, thinness, etc.. Yet they are so desperate to believe they are better people than competing white interest groups (amazing how unself-aware they are about how obvious this is) that they just don’t want to bring looksism to your attention. Upon presentation, this will receive the “yes, that’s bad too” treatment, and then it won’t be talked about any more. Looksism will continue unabated, and indeed it may intensify as some other isms decline.
2. It is worth keeping this information in mind when trying to hire people or find untapped sources of talent.
South Sudan, for instance, recently destroyed nearly 60,000 doses it received from Covax; Malawi destroyed 20,000. Neither were able to distribute their entire allotments before the vaccines expired. Kenya, with more than 50 million people, received over a million doses from Covax in early March, but had used less than one-fifth by late April. The Ivory Coast similarly distributed less than a quarter of the over 500,000 doses it received in late February, raising fears that doses will expire before they are used. The problem goes beyond lower-income countries. More than 600,000 Covax-provided AstraZeneca vaccines sit in Canada at risk of spoilage, while Canadians debate whether it is safe to use them. Vaccinations can begin to confer meaningful protection in under 14 days. Freed from freezers, these vaccines could have saved many lives in Peru, India or Brazil, where the pandemic is raging.
Here is more from Zeke Emanuel and Govind Persad (NYT).
For the last year and a half I have been shouting from the rooftops, “invest in capacity, build more factories, shore up the supply lines, spend billions to save trillions.” Fortunately, some boffins in the Biden administration have found a better way, “the US supports the waiver of IP protections on COVID-19 vaccines to help end the pandemic.”
Waive IP protections. So simple. Why didn’t I think of that???
Patents are not the problem. All of the vaccine manufacturers are trying to increase supply as quickly as possible. Billions of doses are being produced–more than ever before in the history of the world. Licenses are widely available. AstraZeneca have licensed their vaccine for production with manufactures around the world, including in India, Brazil, Mexico, Argentina, China and South Africa. J&J’s vaccine has been licensed for production by multiple firms in the United States as well as with firms in Spain, South Africa and France. Sputnik has been licensed for production by firms in India, China, South Korea, Brazil and pending EMA approval with firms in Germany and France. Sinopharm has been licensed in the UAE, Egypt and Bangladesh. Novavax has licensed its vaccine for production in South Korea, India, and Japan and it is desperate to find other licensees but technology transfer isn’t easy and there are limited supplies of raw materials:
Virtually overnight, [Novavax] set up a network of outside manufacturers more ambitious than one outside executive said he’s ever seen, but they struggled at times to transfer their technology there amid pandemic travel restrictions. They were kicked out of one factory by the same government that’s bankrolled their effort. Competing with larger competitors, they’ve found themselves short on raw materials as diverse as Chilean tree bark and bioreactor bags. They signed a deal with India’s Serum Institute to produce many of their COVAX doses but now face the realistic chance that even when Serum gets to full capacity — and they are behind — India’s government, dealing with the world’s worst active outbreak, won’t let the shots leave the country.
Plastic bags are a bigger bottleneck than patents. The US embargo on vaccine supplies to India was precisely that the Biden administration used the DPA to prioritize things like bioreactor bags and filters to US suppliers and that meant that India’s Serum Institute was having trouble getting its production lines ready for Novavax. CureVac, another potential mRNA vaccine, is also finding it difficult to find supplies due to US restrictions (which means supplies are short everywhere). As Derek Lowe said:
Abolishing patents will not provide more shaker bags or more Chilean tree bark, nor provide more of the key filtration materials needed for production. These processes have a lot of potential choke points and rate-limiting steps in them, and there is no wand that will wave that complexity away.
Technology transfer has been difficult for AstraZeneca–which is one reason they have had production difficulties–and their vaccine uses relatively well understood technology. The mRNA technology is new and has never before been used to produce at scale. Pfizer and Moderna had to build factories and distribution systems from scratch. There are no mRNA factories idling on the sidelines. If there were, Moderna or Pfizer would be happy to license since they are producing in their own factories 24 hours a day, seven days a week (monopolies restrict supply, remember?). Why do you think China hasn’t yet produced an mRNA vaccine? Hint: it isn’t fear about violating IP. Moreover, even Moderna and Pfizer don’t yet fully understand their production technology, they are learning by doing every single day. Moderna has said that they won’t enforce their patents during the pandemic but no one has stepped up to produce because no one else can.
The US trade representative’s announcement is virtue signaling to the anti-market left and will do little to nothing to increase supply.
What can we do to increase supply? Sorry, there is no quick and cheap solution. We must spend. Trump’s Operation Warp Speed spent on the order of $15 billion. If we want more, we need to spend more and on similar scale. The Biden administration paid $269 million to Merck to retool its factories to make the J&J vaccine. That was a good start. We could also offer Pfizer and Moderna say $100 a dose to produce in excess of their current production and maybe with those resources there is more they could do. South Africa and India and every other country in the world should offer the same (India hasn’t even approved the Pfizer vaccine and they are complaining about IP!??) We should ease up on the DPA and invest more in the supply chain–let’s get CureVac and the Serum Institute what they need. We should work like hell to find a substitute for Chilean tree bark. See my piece in Science co-authored with Michael Kremer et. al. for more ideas. (Note also that these ideas are better at dealing with current supply constraints and they also increase the incentive to produce future vaccines, unlike shortsighted patent abrogation.)
Bottom line is that producing more takes real resources not waving magic patent wands.
You may have gathered that I am angry. I am indeed angry that the people in power think they can solve real problems on the cheap and at someone else’s expense. This is not serious. I am also angry that they are sending the wrong message about business, profits and capitalism. So let me end on positive note. Like the Apollo program and Dunkirk, the creation of the mRNA vaccines by Pfizer and Moderna should be lauded with Nobel prizes and major movies. Churchill called the rescue at Dunkirk a “miracle of deliverance,” well the miracle of Moderna will rescue many more. Not only was a vaccine designed in under a year, an entirely new production process was set up to produce billions of doses to rescue the world. The creation of the mRNA vaccines was a triumph of science, logistics, and management and it was done at a speed that I had thought possible only for past generations.
I am grateful that greatness is still within our civilization’s grasp.
Addendum: Lest I be accused of being reflexively pro-patent, do recall the Tabarrok curve.
I thought the meeting went well. I made four points.
- It is not too late to do more.
- We should invest in nasal and oral vaccines.
- We should vaccinate the world.
- We should stretch doses through fractional dosing and delaying the second dose, this will be important to vaccinate the world quickly.
One observation. Lots of people are talking about vaccine hesitancy but I am one of the few people who have been talking about nasal and oral vaccines which are the only really solid approach to the issue that I have seen.
My best line:
The unvaccinated are the biggest risk for generating mutations and new variants. You have heard of the South Africa and Brazilian variants, well the best way to protect your constituents from these and other variants is to vaccinate South Africans and Brazilians.
I also got in the last word in Q&A when discussing the pause of J&J:
For the rest of the world it is important to underline that it is most important to get vaccinated now. Use the AstraZeneca vaccine, use the Johnnson & Johnson vaccine…don’t wait for Moderna or Pfizer, it is going to take too long…start your vaccination program early…vaccinate as quickly as possible, that is the route to health and wealth.
See Western Warnings Tarnish Vaccines the World Badly Needs for the beginnings of a disaster. Note that if J&J and AZ are tarnished or knocked out of the vaccine arsenal then dose stretching and investing in more capacity are going to be even more important.
I also submitted five excellent and important pieces to Congress:
Canadian statement on delaying the second dose.
National Advisory Committee on Immunization (NACI) Canada. 2021. “COVID-19 Vaccine Extended Dose Interval for Canadians: NACI Recommendation.” Government of Canada. March 3, 2021. https://www.canada.ca/en/public-health/services/immunization/national-advisory-committee-on-immunization-naci/rapid-response-extended-dose-intervals-covid-19-vaccines-early-rollout-population-protection.html.
Value of vaccine capacity and additional investments.
Castillo, Juan Camilo, Amrita Ahuja, Susan Athey, Arthur Baker, Eric Budish, Tasneem Chipty, Rachel Glennerster, et al. 2021. “Market Design to Accelerate COVID-19 Vaccine Supply.” Science, February. https://doi.org/10.1126/science.abg0889.
Efficacy of the first dose from NEJM.
Skowronski, Danuta, and Gaston Serres De. 2021. “Letter to the Editor on Safety and Efficacy of the BNT162b2 MRNA Covid-19 Vaccine.” New England Journal of Medicine, February 17, 2021. https://doi.org/10.1056/NEJMc2036242.
Overview of dose stretching policies (with links in the online version).
Tabarrok, Alex. 2021. “What Are We Waiting For?” Washington Post, February 12, 2021, sec. Outlook. https://www.washingtonpost.com/outlook/2021/02/12/first-doses-vaccine-rules-fda/
A plan to vaccinate the world.
Agarwal, Ruchir, and Tristan Reed. 2021. “How to End the COVID-19 Pandemic by March 2022” SSRN. 2021. https://documents.worldbank.org/en/publication/documents-reports/documentdetail/181611618494084337/how-to-end-the-covid-19-pandemic-by-march-2022
Second-generation black Americans have been inadequately studied in prior quantitative research. The authors seek to ameliorate this research gap by using the Current Population Survey to investigate education and wages among second-generation black Americans with a focus on Nigerian Americans. The latter group has been identified in some qualitative studies as having particularly notable socioeconomic attainments. The results indicate that the educational attainment of second-generation Nigerian Americans exceeds other second-generation black Americans, third- and higher generation African Americans, third- and higher generation whites, second-generation whites, and second-generation Asian Americans. Controlling for age, education, and disability, the wages of second-generation Nigerian Americans have reached parity with those of third- and higher generation whites. The educational attainment of other second-generation black Americans exceeds that of third- and higher generation African Americans but has reached parity with that of third- and higher generation whites only among women. These results indicate significant socioeconomic variation within the African American/black category by gender, ethnicity, and generational status that merits further research.
It is called Do Not Disturb: The Story of a Political Murder and an African Regime Gone Bad, and so far it is very good. Here is one bit:
As a Rwandan psychologist once told me: “To show emotional reserve is considered a sign of high standing. You do not just pour out your heart in Rwanda. You do not cry. It’s the opposite of Western oversharing, a form of stoicism.
A culture that glories in its impenetrability, that sees virtue in misleading: to someone proposing to write a nonfiction account embracing many of the most controversial episodes in Rwandan history, it posed a bit of a challenge.
Recommended, I will continue reading, and this one is likely to make the “best non-fiction of the year” list.
4. Survey on body-worn police cameras, mostly positive results.